Comparison
Semaglutide vs Retatrutide
Single agonist versus triple agonist
The key difference
Semaglutide targets only GLP-1. Retatrutide targets GLP-1, GIP, and glucagon receptors at once.
| Semaglutide | Retatrutide | |
|---|---|---|
| Class | GLP-1 receptor agonist | Triple GIP / GLP-1 / glucagon receptor agonist |
| Evidence | FDA-approved drug | Human clinical trials |
| Status | Prescription drug. FDA-approved for specific indications. | Investigational. Not FDA-approved. |
| Also known as | Ozempic, Wegovy, Rybelsus | — |
| Researched for | Weight & metabolism | Weight & metabolism |
| Evidence strength | FDA-approved drug | Human clinical trials |
What else differs
- Semaglutide has years of real-world use and outcome data, including cardiovascular outcomes.
- Retatrutide has not completed phase 3 trials and is not approved.
- Comparing them directly is difficult because no completed head-to-head trial exists.
Bottom line
Semaglutide has the deepest track record; retatrutide is still being studied.
Read the research
Semaglutide on PubMed →
Retatrutide on PubMed →
Educational content, not medical advice. This page does not recommend or dose any substance. Compounds that are not FDA-approved have not been established as safe or effective in people.